

ORAMED PHARMACEUTICALS INC.

Form 8-K

November 03, 2014

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 3, 2014

ORAMED PHARMACEUTICALS INC.  
(Exact name of registrant as specified in its charter)

DELAWARE (State or Other Jurisdiction of Incorporation)	001-35813 (Commission File Number)	98-0376008 (IRS Employer Identification No.)
Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel (Address of Principal Executive Offices)		91390 (Zip Code)
	+972-2-566-0001 (Registrant's telephone number, including area code)	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01.                   REGULATION FD DISCLOSURE.

As previously announced, on November 3, 2014, Oramed Pharmaceuticals Inc., or Oramed, will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, Oramed's proprietary oral insulin capsules to treat type 1 diabetes. On the same day, Oramed posted to its website a presentation containing key top line results from the Phase IIa clinical trial. A copy of this presentation is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01.                   FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Presentation

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORAMED PHARMACEUTICALS  
INC.

By: /s/ Nadav Kidron  
Name: Nadav Kidron  
Title: President and CEO

November 3, 2014

---

---